A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.
Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Drug Resistance, Neoplasm
Female
Genetic Variation
Humans
Immunotherapy
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Receptors, KIR3DS1
/ genetics
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 05 2019
15 05 2019
Historique:
received:
16
09
2018
revised:
14
12
2018
accepted:
04
02
2019
pubmed:
16
2
2019
medline:
17
7
2020
entrez:
16
2
2019
Statut:
ppublish
Résumé
PD-(L)1-blocking antibodies have clinical activity in metastatic non-small cell lung cancer (NSCLC) and mediate durable tumor remissions. However, the majority of patients are resistant to PD-(L)1 blockade. Understanding mechanisms of primary resistance may allow prediction of clinical response and identification of new targetable pathways. Peripheral blood mononuclear cells were collected from 35 patients with NSCLC receiving nivolumab monotherapy. Cellular changes, cytokine levels, gene expression, and polymorphisms were compared between responders and nonresponders to treatment. Findings were confirmed in additional cohorts of patients with NSCLC receiving immune checkpoint blockade. We identified a genetic variant of a killer cell immunoglobulin-like receptor (KIR) We identified an association of the
Identifiants
pubmed: 30765392
pii: 1078-0432.CCR-18-3041
doi: 10.1158/1078-0432.CCR-18-3041
doi:
Substances chimiques
KIR3DS1 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Receptors, KIR3DS1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3026-3034Informations de copyright
©2019 American Association for Cancer Research.